General Information of Drug (ID: DM0QZBN)

Drug Name
Ibandronate
Synonyms
BFQ; Acid ibandronico; Ibandronic Acid; Bisphosphonate 2; R484; RPR 102289A; Bondronat (TN); Boniva (TN); Bonviva (TN); Ibandronic acid (INN); Ibandronic acid [INN:BAN]; RPR-102289A; Ibandronic acid, sodium salt, monohydrate; Roche brand of ibandronic acid, sodium salt, monohydrate; [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid; [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID; (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid; (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate
Indication
Disease Entry ICD 11 Status REF
Hypercalcaemia 5B91.0 Approved [1]
Osteoporosis FB83.0 Approved [2]
Therapeutic Class
Bone Density Conservation Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 319.23
Logarithm of the Partition Coefficient (xlogp) -4.1
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 4.1 +/- 2.6 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.1 +/- 0.6 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
The bioavailability of drug is 0.63% [3]
Clearance
The total clearance of drug is 84-160 mL/min [5]
Elimination
55% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 37 - 157 hours [5]
Metabolism
The drug is not metabolised [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.13063 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [7]
Vd
The volume of distribution (Vd) of drug is 90-368 L [3]
Chemical Identifiers
Formula
C9H23NO7P2
IUPAC Name
[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
Canonical SMILES
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
60852
CAS Number
114084-78-5
DrugBank ID
DB00710
TTD ID
D08SJZ
ACDINA ID
D00319
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Geranyltranstransferase (FDPS) TTIKWV4 FPPS_HUMAN Modulator [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [9]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Gene/Protein Processing [10]
Ras-related protein Rap-1A (RAP1A) OT5RH6TI RAP1A_HUMAN Post-Translational Modifications [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ibandronate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Ibandronate caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [12]
Framycetin DMF8DNE Moderate Increased risk of hypocalcemia by the combination of Ibandronate and Framycetin. Alcoholic liver disease [DB94] [13]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Ibandronate and Inotersen. Amyloidosis [5D00] [14]
Streptomycin DME1LQN Moderate Increased risk of hypocalcemia by the combination of Ibandronate and Streptomycin. Bacterial infection [1A00-1C4Z] [13]
Netilmicin DMRD1QK Moderate Increased risk of hypocalcemia by the combination of Ibandronate and Netilmicin. Bacterial infection [1A00-1C4Z] [13]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Ibandronate and Iodipamide. Cholelithiasis [DC11] [15]
Ketoprofen DMRKXPT Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Ketoprofen. Chronic pain [MG30] [14]
Mefenamic acid DMK7HFI Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Mefenamic acid. Female pelvic pain [GA34] [14]
Pentamidine DMHZJCG Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Pentamidine. Fungal infection [1F29-1F2F] [13]
Bumetanide DMRV7H0 Moderate Increased risk of hypocalcemia by the combination of Ibandronate and Bumetanide. Heart failure [BD10-BD1Z] [16]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Ibandronate and Etelcalcetide. Hyper-parathyroidism [5A51] [14]
Meclofenamic acid DM05FXR Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [17]
Iron DMAP8MV Moderate Decreased absorption of Ibandronate due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [18]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [13]
Exjade DMHPRWG Major Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Exjade. Mineral absorption/transport disorder [5C64] [19]
Gallium nitrate DMF9O6B Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Gallium nitrate. Mineral excesses [5B91] [13]
Naproxen DMZ5RGV Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Naproxen. Osteoarthritis [FA00-FA05] [14]
Etodolac DM6WJO9 Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Etodolac. Pain [MG30-MG3Z] [14]
Ibuprofen DM8VCBE Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Ibuprofen. Pain [MG30-MG3Z] [14]
Choline salicylate DM8P137 Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Choline salicylate. Postoperative inflammation [1A00-CA43] [14]
Bromfenac DMKB79O Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Bromfenac. Postoperative inflammation [1A00-CA43] [14]
Temsirolimus DMS104F Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Temsirolimus. Renal cell carcinoma [2C90] [13]
Colistimethate DMZ9BMU Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Colistimethate. Respiratory infection [CA07-CA4Z] [13]
Salsalate DM13P4C Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Salsalate. Rheumatoid arthritis [FA20] [14]
Flurbiprofen DMGN4BY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Ibandronate and Flurbiprofen. Rheumatoid arthritis [FA20] [14]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Sulfasalazine. Rheumatoid arthritis [FA20] [13]
Salicyclic acid DM2F8XZ Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Salicyclic acid. Seborrhoeic dermatitis [EA81] [17]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [13]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Ibandronate and Sirolimus. Transplant rejection [NE84] [20]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Ibandronate and Tacrolimus. Transplant rejection [NE84] [20]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Ibandronate and Olsalazine. Ulcerative colitis [DD71] [13]
⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Ammonia E00007 222 Alkalizing agent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ibandronic acid 150 mg tablet 150 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Ibandronate FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3059).
3 Reginster JY, Neuprez A, Bruyere O: Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941.
4 BDDCS applied to over 900 drugs
5 FDA Approved Drug Products: Boniva Ibandronate Oral Tablets
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001 Jun 1;61(11):4418-24.
10 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
11 Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast Cancer Res. 2008;10(1):R4. doi: 10.1186/bcr1845. Epub 2008 Jan 11.
12 Cerner Multum, Inc. "Australian Product Information.".
13 Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D "Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity." Am J Kidney Dis 41 (2003): E18. [PMID: 12778436]
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
16 Product Information. Zometa (zoledronic acid). Novartis Pharmaceuticals, East Hanover, NJ.
17 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
18 Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
19 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
20 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.